Keyword: Andrew Witty

CEO Emma Walmsley just put cancer back on the front burner, but with its $5 billion Tesaro buy and in-house candidates, the pipeline is pumping, she says.

Luc Debruyne, who has served as GlaxoSmithKline's president of vaccines for five years, will leave the company at the end of the year.

As Glaxo CEO, Andrew Witty was prepping for a future rife with payer pressure that could hit pharma hard. And now, he'll apply that pressure.

Sanofi Pasteur’s chief quality officer says vaccinemakers need help tackling a lurking challenge: global regulatory entanglements.

If any GlaxoSmithKline investors were hoping new CEO Emma Walmsley would break with her predecessor and pursue a split-up, they got a rude awakening Wednesday.

Andrew Witty's nine-year GSK CEO tenure saw him break with his peers—sometimes, to the tune of heavy criticism—more than once.

With stellar vaccine sales for GlaxoSmithKline and Bexsero, GSK is building a $175 million plant in Germany to expand production of the meningococcal B shot.

Investors who wanted GSK to sink its CEO-designate Emma Walmsley's base salary may not be happy with her just-announced compensation package.

As incoming GlaxoSmithKline CEO Emma Walmsley gets ready to move into the company’s top spot, shareholders have objections—and they center on her pay package.

During Andrew Witty’s final full year at GSK, vaccines outgrew each of GSK’s other units.